Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.250
0.00 (0.00%)
At close: Aug 25, 2025, 4:00 PM
3.330
+0.080 (2.46%)
After-hours: Aug 25, 2025, 6:59 PM EDT
Grace Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Grace Therapeutics stock has a target of 12, which predicts a 269.23% increase from the current stock price of 3.25.
Price Target: $12 (+269.23%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 18, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Grace Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +269.23% | Feb 18, 2025 |
Financial Forecast
Revenue This Year
439.58K
Revenue Next Year
n/a
from 439.58K
EPS This Year
-1.74
from -0.79
EPS Next Year
-0.84
from -1.74
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 19.7M | 47.3M |
| Avg | n/a | 10.3M | 45.9M |
| Low | n/a | 1.3M | 44.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | 360.5% |
| Avg | - | - | 347.4% |
| Low | - | - | 329.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.58 | -0.51 | 0.53 |
| Avg | -0.84 | -0.58 | 0.51 |
| Low | -1.08 | -0.64 | 0.49 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.